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Background—The goal of the study was to test the validity of additive versus synergistic versus
underadditive versions of brain reserve theory within the context of HIV/AIDS. In addition, it tested
the convergent validity of 2 operational definitions of premorbid reserve: verbal IQ (VIQ) and a
family history (FH) of substance abuse or dependence.
Methods—Seventy HIV-1 seronegative and 115 HIV-1 seropositive male and female volunteers
were assigned to 4 subgroups defined by the crossing of a VIQ score < versus ≥ 90 with the presence
versus absence of a paternal history of alcohol, cocaine, or opiate abuse or dependence. The principal
dependent measure was the P300 event related brain potential elicited during the Stroop color-word
interference task.
Results—The principal finding was an underadditive effect of FH plus HIV/AIDS on P300 area
over the frontal region: FH reduced frontal scalp P300 to such a degree that the additional effects of
HIV/AIDS were blunted. The alternate operational definition of brain reserve, VIQ, had no effect
on P300 and did not alter the effects of HIV/AIDS.
Conclusions—Familial risk for substance dependence and low VIQ compromise different aspects
of brain structure and/or function and therefore differ in their relationship to HIV/AIDS and P300.
Genetic differences associated with familial risk may reduce brain reserve to such a degree that the
neurophysiological effects of HIV/AIDS can no longer be measured.
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1. Introduction
The rationale for the present study derives from a neuropsychological theory of brain reserve
(BR). BR theory views premorbid variables, such as VIQ, educational attainment, or brain size,
as important factors explaining the wide variation in functional outcomes after brain disease
or injury across patients with similar structural deficits. It has been invoked by investigators
studying HIV/AIDS (Stern et al., 1996; Tomasi et al., 2006), dementia (Spitznagel and
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Tremont, 2005; Zhang et al., 1990), Alzheimer's Disease (Bennett et al., 2003; Scarmeas et al.,
2004; Stern et al., 1994), multiple sclerosis (Cader et al., 2006), and other disorders (Farmer
et al., 2002; Kesler et al., 2003; Ropacki et al., 2003), as well as normal aging (Stern et al.,
2004).
Since 1988 (Katzman et al., 1988), several versions of BR theory have been proposed.
According to one version, better premorbid function (i.e., a higher level of brain reserve) is
viewed as protective against the effects of neuropsychiatric disease because the premorbid
level is more distant from the threshold for clinical impairment, and the new level of functioning
attained after disease onset is therefore less likely to cross the threshold. This version has been
characterized as passive (Satz et al., 1993). It views the disease or injury as subtracting capacity
from the premorbid reserve but does not recognize a role for the brain in actively compensating
for the loss. The top panel in Figure 1 illustrates this theory applied to hypothetical data from
a forced-choice task in which 50% correct represents the measurement floor (i.e., a chance
level of accuracy).
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A second version of BR theory is described as active. In this version, high levels of reserve are
hypothesized to antagonize the adverse effects of neuropsychiatric disease (Pereda et al.,
2000; Staff et al., 2004; Stern, 2002). In contrast, low levels amplify adverse effects. The
proposal has a simplistic and intuitive appeal--a larger or more synaptically complex brain
(Katzman et al., 1988; Mori et al., 1997; Wallace et al., 1992) should be more successful in
compensating for the effects of disease by relying upon its larger reserve of existing resources
and recruiting alternative strategies and circuits. However, a brain already compromised in its
size or function, as a result of a genetic or environmental deficit, should be less successful. The
middle panel of Figure 1 illustrates this theoretical model.
A third version of brain reserve theory is shown in the bottom panel of Figure 1. It assumes a
more powerful effect of reduced premorbid reserve on brain function. As a result, the level of
function approaches the minimum, and the disease can have no further detrimental effect.
Unlike other versions, this version of BR theory proposes that the strength of the correlation
(i.e., neuroanatomical overlap) between the measures of premorbid reserve and outcome is
critical in determining whether patients with greater premorbid reserve will be more versus
less impaired following disease onset.
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The present study is significant for it tests the relative validity of these three alternate versions
of BR theory within the context of HIV/AIDS. It was hypothesized that the nature of the
relationship between premorbid reserve and HIV/AIDS would vary as a function of how
premorbid reserve was defined and of the association between the definition and outcome
variable. Dependence on a specific operational definition of reserve could be interpreted as a
weakness of the general theory.
Another reason justifying the present test of multiple operational definitions of premorbid
reserve is the limitation of traditional definitions of reserve, e.g., IQ and educational level.
These definitions can be criticized, for example, as overly-descriptive and non-causal. Also,
in many studies, they are confounded with the variable used to measure disease outcome, which
is often another neuropsychological or achievement test (Tuokko et al., 2003). In addition, IQ
and educational level overlap with other, more distal factors with greater relevance to genetic
endowment. In recognition of these limitations, BR was defined in this study by one of the
traditional metrics—verbal IQ--in the first set of analyses and by a metric--the presence/
absence of paternal alcohol or drug dependence--more relevant to genetic risk for diminished
cognitive function, but not independent of the traditional metrics (Finn and Hall, 2004;
McIntosh et al., 2005), in the second analysis set.
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A fair comparison of the 3 alternate versions of BR theory, and of 2 operational definitions of
BR, requires an outcome variable which is continuous and linear over a broad range. For this
reason, the P300 event related brain potential was chosen. P300 is a positive-going change in
the electroencephalogram which occurs approximately 300−500 msec after the presentation
of a stimulus that is novel or otherwise salient, e.g., attended. It has been defined as reflecting
the activation of a limited capacity attentional system related to both orienting and working
memory (Lefevre at al., 2005; Linden, 2005; Nieuwenhuis et al., 2005; Polich, 2004).
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Several reasons justify the choice of P300 as the outcome variable. First, P300 shows
remarkable measurement sensitivity over a broad range (Polich, 1998; Polich, 2004; Polich
and Herbst, 2000) with excellent, r ≅ 0.8, test-retest reliability (Williams et al., 2005).
Accordingly, it is ideal for testing interactions between factors and minimizing spurious
findings which originate from ceiling or floor effects. Second, P300 reflects global functional
capacity. Its generators involve circuits within both frontal and nonfrontal regions (Linden,
2005; Ardekani et al., 2002; Bledowski et al., 2004; Clark et al., 2000; Kiehl et al., 2005) and
its amplitude and latency are correlated with other measures of global capacity, including IQ
(Hansell et al., 2005). Accordingly, it is an appropriate metric for detecting individual
differences in brain reserve. Third, the P300 has a long history of value for detecting the effects
of HIV/AIDS (Bauer and Shanley, 2006; Polich and Basho, 2002; Polich et al., 2000; Syndulko
et al., 1994) and familial substance dependence (Begleiter et al., 1984; Viana-Wackerman et
al., 2007; Hesselbrock et al., 2001; Polich et al., 1994; Porjesz et al., 2005). Indeed, the
literatures documenting decrements in P300 amplitude, or delays in P300 latency, associated
with a family history of substance dependence or a personal history of HIV/AIDS are
remarkably consistent.

2. Methods
2.1 Participants and Screening Procedures
One-hundred-fifteen HIV-1 seropositive participants were recruited via advertisements posted
within outpatient Infectious Disease Clinics in the greater Hartford, CT region. Interested
individuals were invited to telephone a member of the research staff for eligibility screening.
The telephone interview included questions about demographic characteristics, general
medical status, substance use, and psychiatric symptoms. Individuals who passed the initial
telephone screen were invited to visit the Health Center on a subsequent day, during which an
IRB-approved consent form and a medical records release were signed. Additional eligibility
screening and laboratory evaluations were performed on that day.
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The most common method for recruiting the 70 members of the HIV-1 seronegative group was
word-of-mouth advertising provided by the seropositive participants. HIV-1 seronegative
volunteers were invited to telephone the research assistant for initial screening and were
brought to the Health Center for further screening. They were subject to the same protocol as
the HIV/AIDS patients.
After completing the informed consent and medical release documents, all participants were
asked to provide a blood sample for laboratory confirmation of HIV serostatus. The clinical
laboratory evaluation also included CBC with differential, HIV RNA viral load, CD4
lymphocyte count and percent, VDRL, HBV screen, HCV, toxoplasmosis and cytomegalovirus
antibody titers, renal and liver function, serum protein, albumin, and G-6-PD. Toxicological
analyses for cocaine, opiates, amphetamine, and marijuana were performed on urine samples
(Ontrak™, Varian Inc., Palo Alto, CA) and a breathalyzer was used to detect recent alcohol
use. In addition, an Optec 2000 Vision Tester™ was used to confirm normal color vision and
acuity (with correction).
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A structured psychiatric interview, viz., the CDIS-IV (American Psychiatric Association,
1994; Robins et al., 2002), used for detecting DSM-IV Axis I and II disorders, was then
administered by a research assistant formally trained in its administration and with 11 years of
relevant experience. Participants also completed questionnaires or brief interviews assessing
medical history, medication use, parental psychopathology, demographics, psychiatric
symptoms, alcohol and drug use, and cognitive status. The assessments included the Addiction
Severity Index (ASI; McLellan et al., 1980), Michigan Alcoholism Screening Test (MAST;
Selzer, 1971), Drug Abuse Screening Test (DAST-10; Skinner, 1982), and Beck Depression
Inventory Version II (BDI-II; Beck et al., 1996). In addition, the Kaufman Brief Intelligence
Test (KBIT; Kaufman and Kaufman, 1990) was administered to derive an estimate of VIQ.
Exclusion criteria included pregnancy, seizures, mental retardation, neurosurgery, and a history
of head injury with loss of consciousness for greater than 10 minutes. In addition, participants
were required to have no acute illness, an IQ score greater than 70, and no major neurological,
psychiatric (i.e., DSM-IV-defined schizophrenia or bipolar disorder) or medical (i.e.,
hypertension, chronic obstructive pulmonary disease, Type 1 diabetes, cirrhosis, hepatic
encephalopathy, ocular disorders, etc.) disorders unrelated to HIV/AIDS. Positive urine
toxicology or breathalyzer tests or recent (past year) dependence upon alcohol, cocaine, or
opiates were also exclusionary. However, current use of methadone was not.
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For the analysis, HIV-1 seropositive and seronegative participants were assigned to one of two
subgroups defined by a split (< 90 vs. ≥ 90) on the median verbal IQ score for the entire sample.
In addition, they were further stratified by the presence (FH+) versus absence (FH−) of a report
during the interview that the biological father had been diagnosed or treated for an alcohol,
cocaine, or opioid use disorder. It would have been preferable to conduct direct interviews with
parents to verify the presence versus absence of substance dependence. But, the majority of
these participants (mean age = 39 yrs) were unable or unwilling to involve their parents in the
study.
2.2 Data Collection
Tin EEG electrodes were applied to 31 scalp sites positioned by an electrode cap (ElectroCap
International, Eaton, Ohio). A reference electrode was taped over the bridge of the nose. The
ground electrode was applied to the middle of the forehead. Interelectrode impedance was
maintained below 5 Kilohms.
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After electrode application was complete, the participant was escorted into a sound-shielded
chamber and seated in a comfortable chair. The chair faced a 14-inch computer monitor used
for the presentation of visual stimuli. A set of shielded stereo headphones, used for auditory
stimulus presentation, and other devices (response keys), were located in the immediate
proximity of the chair.
Participants performed a discreet trials version (Duncan-Johnson and Kopell, 1981; Bauer and
Hesselbrock, 1999) of the Stroop Test (MacLeod, 1991; Stroop, 1935, van Venn and Carter,
2005) in which the stimuli, i.e., the words RED, BLUE, or TOWN, were presented in a red or
blue font on the computer monitor. The 6 combinations of words and font colors could later
be reduced to three types of trials. These were: (1) compatible font color-word combinations
(e.g., the word “BLUE” displayed in blue font), incompatible color-word combinations (e.g.,
the word “BLUE” displayed in red font), and unrelated (e.g., the word “TOWN” displayed in
blue font) combinations.
Three hundred word stimuli were presented with equal probability at a rate of one stimulus
every 2.3 seconds for 200 msec each. Participants were asked to indicate the color of the font
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by pressing one of two response keys within a response deadline of 1500 msec. They were also
asked to ignore the word.
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The electroencephalogram was recorded throughout the task. For the detection of eyeblink and
eye movement artifacts, a pair of electrodes were placed diagonally above and below the left
eye. The 31 channels of the EEG and 1 channel of eye movement (EOG) activity were
appropriately amplified (EEG gain=20K, EOG gain=2K) and filtered (bandpass=0.01−12 Hz)
using a SA Instrumentation Company amplification system. Along with markers indicating
stimulus and response onsets, the EEG and EOG channels were routed to an A/D converter,
and sampled at a rate of 200 Hz for 50 msec preceding and 950 msec following the onset of
each stimulus. During off-line computations, single trial data were sorted by electrode and trial
type. Before averaging, trials containing an eye movement deviation greater than 50 μV were
deleted. Trials with A/D converter overflow and incorrect responses were also deleted.
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Time-point averaged waveforms were then created from a minimum of 20 accepted trials of
each of the compatible and incompatible types. P300 was estimated by the summated area
under the curve between 250 and 500 msec following stimulus onset. This area measure was
chosen over a peak amplitude measure because a distinct peak was not consistently present in
the records of all 185 subjects under both trial conditions. The interval of 250−500 msec was
chosen because it is a time period proximal to the discrimination of the stimuli and the execution
of the motor response.
Behavioral performance indices were also recorded during the task and summarized off-line.
Average reaction time and the percentage of trials with correct responses were sorted by
incompatible and compatible trial types and preserved for analysis.
2.3 Data Analysis
The 8 groups of subjects were initially compared on background characteristics. Pearson's ChiSquare Test evaluated group equivalence on categorical variables. A three factor ANOVA
served the same purpose for continuous variables. Significant interaction effects revealed by
ANOVA were further evaluated with Tukey post hoc tests.
Behavioral performance was analyzed for each major design. Reaction time and response
accuracy were analyzed separately via repeated measures ANOVA with trial type (compatible,
incompatible) as a within-subjects factor, and the three grouping factors.
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In an attempt to reduce the number of analyses on P300 area, and the attendant risk of Type I
error, a factor analysis was performed on P300 area across the 31 electrode sites. The goal was
to find topographic regions of homogeneity which could be reduced to a single score. A
principal components analysis followed by varimax rotation yielded two factors which
explained most of the variance across the 31 sites. The frontal sites exhibited greater loadings
on the first factor. The sites around and posterior to the central sulcus exhibited greater loadings
on the second factor. Highly similar factor structures were obtained for both incompatible and
compatible trial data. We therefore chose to calculate average area scores representing P300
amplitude within anterior (FP1, FP2, AF1, AF2, F3, F4, F5, F7, FZ, FC2, FC4, FC5, FC6) and
posterior (C3, C4, CZ, CP1, CP2, CP5, CP6, P3, P4, PZ, T7, T8, P7, P8, PO1, PO2, O1, O2)
regions. These scores were analyzed via repeated measures ANOVAs with HIV/AIDS, VIQ,
and FH as grouping factors, and trial type and scalp region as repeated measures factors.
Of principal interest in the P300 analyses was the pattern of relationship between either FH
and VIQ (as putative indices of brain reserve) and HIV/AIDS. As we show in Figure 1a, a
simple additive relationship between HIV/AIDS and brain reserve would be indicated by
significant main effects of each with no significant interaction. However, a significant
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interaction could indicate either a synergistic (Figure 1b) or underadditive (Figure 1c)
relationship. The latter pattern was hypothesized.
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3. Results
3.1 Background Characteristics
The participants included in the analyses can be broadly characterized as men and women of
various racial/ethnic origins, approximately 39 years of age, educated for an average of 11.85
years, and possessing either no or mild symptoms of depression. Many had histories of illicit
drug abuse and/or alcohol abuse; however, DSM-IV-defined dependence on illicit drugs or
alcohol during the year prior to the P300 assessment was exclusionary. The HIV-1 seropositive
participants were remarkably healthy: viral loads were low and CD4+ T-lymphocyte counts
were, in the typical case, greater than 200 cells/μl. Table 1 summarizes the demographic,
substance use, psychological, and medical characteristics of these participants as a function of
their verbal IQ rank relative to the median (< vs. ≥ 90), FH, and HIV-1 serostatus.
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The groups differed on few characteristics. Some differences were expected because they are
related to group assignment. For example, the low and high verbal VIQ groups differed
significantly on years of education by an average of 1.7 yrs [F(1,177)=33.3, p<0.001]. And,
the FH+ group reported an average of 2.2 more alcohol problems on the MAST than the FH−
group [F(1,177)=5.1, p<0.02]. The HIV+ and HIV−groups differed on CD4 cell count [F(1,177)
=105.2, p<0.001].
Some unexpected but small differences occurred for other demographic characteristics. A
lower versus higher VIQ was associated a minor but statistically significant 3.2 unit decrease
in depression symptoms on the BDI-II [F(1,177)=12.9, p<0.001]. In addition, HIV+ subjects
were, on average, 3 yrs older than their HIV− peers [F(1,177)=7.7, p<0.006]. There were no
significant interactions involving the grouping factors.
3.2 Task Performance Results
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The analysis of reaction time revealed a significant effect of trial type [F(1,177)=161.6,
p<0.001]. It was greater when the irrelevant stimulus word and relevant stimulus font cued
incompatible responses than when they cued the same response. Family history modified the
effects of trial type on reaction time [F(1,177)=9.0, p<0.003]: the reaction time difference
between incompatible and compatible trials, i.e., the Stroop effect, was significantly greater in
the FH+ [incompatible trial (M ± SD): 0.63 ± .13; compatible trial: 0.57 ± .13] than FH−
(incompatible: 0.57 ± .12; compatible: 0.53 ± .11) groups. The magnitude of the Stroop effect
did not vary by VIQ [trial type × VIQ: F(1,177)=0.01, p=0.92] or HIV [trial type × HIV: F
(1,177)=0.09, p=0.77].
The analysis of reaction time yielded several other significant effects. Generally, subjects with
a positive family history [0.61 ± .15 vs. 0.54 ± .11; F(1,177)=10.5, p<0.001], or a lower VIQ
[0.61 ± .12 vs. 0.54 ± .14; F(1,177)=12.5, p<0.001], were slower to respond than their FH− or
higher VIQ peers. FH also modified the effects of HIV/AIDS on reaction time [F(1,177)=5.4,
p<0.02] whereas VIQ had no such effect [F(1,177)=1.9, p=0.16]. Unfortunately, the interaction
between FH and HIV/AIDS is not readily interpreted. The absence versus presence of HIV/
AIDS was associated with a reaction time increase of .042 sec among FH− subjects. But, among
FH+ subjects, HIV/AIDS was associated with .053 sec change in the opposite direction. No
other main or interaction effects were significant.
The analysis of performance accuracy yielded an interaction between trial type and FH [F
(1,177)=4.7, P<0.03] which was consistent with the interaction found for reaction time: the
magnitude of the Stroop effect was greater in the FH+ (incompatible: 95.1 ± 7 %; compatible:
Drug Alcohol Depend. Author manuscript; available in PMC 2009 April 1.
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97.3 ± 6 %) than FH− (incompatible: 95.6 ± 8 %; compatible: 96.6 ± 7 %) groups. As in the
analysis of reaction time, there was also a significant main effect of VIQ [F(1,177)=5.4,
p<0.02]. Increased VIQ was associated with an increase in response accuracy from 95.0 ± 6
% to 97.5 ± 6 %. VIQ was again not associated with a change in the magnitude of the Stroop
effect. It also did not interact with HIV.
3.3 P300 Results (Figure 2)
The analysis yielded no significant effects involving VIQ as a factor. Yet, it did yield several
significant effects involving FH and HIV/AIDS. For example, the interaction of FH and HIV/
AIDS was significant [F(1,177)=3.7, p<0.05]. Tukey post hoc tests revealed a decrement in
P300 area associated HIV/AIDS (HIV− = 3497 ± 2774; HIV+ = 2136 ± 2049) in the FH− group.
In the FH+ group, HIV/AIDS was associated with no significant change in P300 (HIV− = 2088
± 4622 vs. HIV+ = 2331 ± 3471). This interaction is illustrated in Figure 3 and is consistent
with the prediction of the underadditive model shown in Figure 1c.
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HIV was also associated with an overall reduction in P300, but only over the anterior scalp
region [HIV × Region: F(1,177)=9.8, p<0.002]. The magnitude of the HIV effect was −920
uV over the anterior region and −197 uV over the posterior region. The 2-way interaction of
HIV and Region was qualified by a complex 4-way interaction that also included trial type and
FH [F(1,177)=4.4, p<0.03]. An examination of the means illustrated in Figure 4 indicates that
P300 was generally larger on compatible than incompatible trials. This difference was more
pronounced at anterior versus posterior electrodes among subjects with no FH and without
HIV/AIDS. Thus, in contrast to the findings from the analysis of reaction time, the analysis of
P300 showed a reduced Stroop effect associated with FH and HIV/AIDS.

4. Discussion
The present study was designed to test the relative validity of three versions of brain reserve
theory within an ethnically-diverse sample of men and women living with HIV/AIDS. It also
contrasted the effects of two alternate operational definitions of the construct for the purpose
of evaluating the generality of the theory. The analyses revealed three major findings: (1) In
contrast to the predictions of the most popular version of brain reserve theory (Figure 1b), high
VIQ did not moderate the adverse effects of HIV/AIDS nor did low VIQ potentiate these
effects; (2) HIV/AIDS and a family history of substance abuse or dependence both reduced
P300 area over the frontal scalp; (3) The effects of HIV/AIDS on frontal P300 area were blunted
among subjects with a positive FH (Figures 1c and 3). The latter finding is consistent with the
underadditive version of BR theory illustrated in Figure 1c and inconsistent with the additive
and synergistic versions illustrated in Figures 1a and 1b..
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Since its initial proposal (Katzman et al., 1988), reserve theory has been subject to several
challenges and criticisms. One criticism is the manner in which the reserve construct has been
defined. In many HIV studies (Stern et al., 1996; Pereda et al., 2000), either VIQ, educational
attainment, or occupational attainment is the definition of convenience. In such studies, the
definition is a proxy for an assemblage of unmeasured factors which may or may not be relevant
to the structural or functional capacity of the brain. For example, HIV/AIDS patients with
higher intelligence or attainment may simply be more motivated, or more experienced with
tests, than their less intelligent or accomplished peers and would accordingly perform better
on any outcome test of cognitive function or achievement. To avoid this ascertainment bias
(Tuokko et al., 2003) in the present study, we employed an outcome test less affected by
motivation and familiarity.
HIV/AIDS patients with higher VIQ or attainment may also be more likely to seek health care
services (Cunningham et al., 2005). As a result, the HIV/AIDS diagnosis may occur at an earlier
Drug Alcohol Depend. Author manuscript; available in PMC 2009 April 1.
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stage of the disease allowing early initiation of treatment. Or, patients with higher VIQ or
attainment may be more compliant with treatment (Borrell et al., 2006). In both instances,
patients with superior “reserve” may accordingly experience a less severe course of the disease
resulting in less impairment. It is important to note that this confound is less of a concern for
the present study because the low (IQ<90 or FH+) and high (IQ≥90 or FH−) reserve groups did
not differ on current measures of illness severity, including CD4 count and viral burden.
Admittedly, current illness severity might not the ideal variable on which to evaluate group
equivalence. The nadir CD4 count during a patient's lifetime may be a better predictor of his/
her current cognitive or neurological status (Valcour et al., 2006).
A third potential problem for the extant theoretical models is the questionable hypothesis of
synergistic interaction of reduced premorbid reserve and HIV/AIDS. Whether low brain
reserve reduces (Figure 3), enhances (Stern et al., 1996), or is independent of, the deleterious
effects of HIV/AIDS may depend critically upon the degree of neuroanatomical and functional
overlap of HIV/AIDS with the chosen operational definition of reserve as well as their
relationships with the outcome measure. The present results suggest greater overlap in the
effects of HIV/AIDS with one definition of reserve, viz., FH, insofar as both affected P300,
whereas the other definition, viz., VIQ, did not. Hence, an interaction between HIV/AIDS and
FH was more probable.
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One should exercise caution in interpreting these results. For example, it is possible that the
degree to which HIV/AIDS interacts with one versus another definition of reserve is dependent
upon the association between the definition and the context (i.e., the cognitive task) within
which disease outcome is evaluated. For this study, we chose the Stroop task because it has
repeatedly been shown sensitive to the effects of FH (e.g., Lovallo et al., 2006) and HIV/AIDS
(Martin et al., 2004). VIQ, in contrast, appears to be more strongly correlated with working
memory than with performance on the Stroop task or similar tasks measuring cognitive control
(Boone et al., 1998).
A second important caveat is the possibility that the effects of FH are explained by a confounded
difference between the FH+ and FH− groups in their personal histories. Mediation by drug use,
or depression severity, appears unlikely because the groups did not differ significantly on these
variables. Furthermore, a past year history of alcohol or drug dependence was exclusionary.
Yet, the groups did differ significantly on the MAST, which measures the lifetime number of
alcohol problems. Specifying MAST scores as a covariate did not affect the results.
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A more likely confound is Antisocial Personality Disorder which we (Bauer and Shanley,
2006) and other groups (see Bauer & Houston, 2004, for a review) have described as an
important mediator of the effects of FH on P300. In fact, the association is of such a magnitude
that statistically controlling for the effects of conduct problems will typically eliminate the
effects of FH on P300 (e.g., Bauer and Hesselbrock, 1999; Viana-Wackerman et al., 2007).
The present demonstration of similar effects of HIV/AIDS and FH on frontal P300 area is
consistent with other reports documenting susceptibility of the frontal brain to HIV-1 (Bauer
and Shanley, 2006; Chang et al., 2003; Cloak et al., 2004; Wu et al., 2006), a family history
of alcoholism (Bauer and Hesselbrock, 2002; Schweinsburg et al, 2004), and attendant factors-e.g., Conduct Disorder/Antisocial Personality Disorder (Bauer and Houston, 2004; Bauer and
Shanley, 2006; Bauer and Hesselbrock, 2001; Hoptman, 2003; Nakano et al., 2006; Raine et
al., 2000; Yang et al., 2005)--which increase the risk for both HIV/AIDS (e.g., Brooner et al.,
1993; Erbelding et al., 2004) and substance abuse/dependence (e.g., Hesselbrock et al., 1985;
McGovern et al., 2006). The demonstration of an interaction between HIV/AIDS and FH also
raises interesting questions regarding genetic vulnerability to neurocognitive impairment in
HIV/AIDS. Admittedly, family history is not an ideal independent variable for testing genetic
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hypotheses because it captures both genetic and environmental effects. An investigation of
candidate genes could be fruitful.
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One possibility for investigation is the COMT gene, for polymorphisms of this gene have been
shown to alter both P300 (Gallinat et al., 2003) and the performance of neurocognitive tasks,
e.g., Stroop (Reuter et al., 2005), which reflect frontal brain function. A second possibility is
the GABRA2 gene on chromosome 4. GABRA2 is likely related to neurocognitive impairment
in HIV/AIDS via it association with intermediate risk factors, including conduct problems
(Dick et al., 2006) and alcohol (Edenberg et al., 2004; Lappalainen et al., 2005; Covault et al.,
2004) and other drug (Agrawal et al., 2006; Dick et al., 2006) dependence. It has also been
linked to an excess of high frequency (fast beta) electroencephalographic power (Edenberg et
al., 2004) generated within the same frontal brain regions (Bauer and Hesselbrock, 2002;
Isotani et al., 2001; Kondakor et al., 1997) where HIV/AIDS exerts significant effects (Bauer
and Shanley, 2006; Chang et al., 2003; Cloak et al., 2004; Wu et al., 2006).
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It is important to not conclude from these findings that a FH of substance abuse/dependence
will blunt all of the neurological effects of HIV/AIDS or the P300 changes associated with
severe disease, i.e., dementia. The HIV-1 seropositive patients enrolled in this study were
generally healthy and without acute illness. Our findings can only be generalized to this
subpopulation. Yet, in the current era of effective antiretroviral therapies--during which acute
illness, dementia, and frailty are less common--the relative contributions of family history and
coexisting psychiatric disorders to functional impairment in HIV/AIDS are greater and
therefore warrant increased attention.
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Figure 1a,b,c.

Alternate versions of brain reserve (BR) theory.
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Figure 2.
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ERP waveforms averaged within the FH-, HIV- group depicting the effects of trial type on
P300 area across 9 representative electrode sites. Area was calculated between the dashed
vertical lines ranges from 250 to 500 msec post-stimulus onset (designated by arrow). Each tic
mark on the x-axis represents 100 msec.
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Figure 3.

Effects of HIV-1 serostatus and a family history of substance abuse or dependence on P300
area. Note the similarity of this relationship to the under-additive theoretical model illustrated
in Figure 1C.
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Figure 4.

Difference in P300 area between compatible and incompatible trials as a function of group and
region. Mean values labelled “a” and “b” are significantly different.
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Age, mean (SD), y
Male, %
Education, mean (SD), y
MAST Score, mean (SD)
DAST-10 Score, mean (SD)
BDI-II Score, mean (SD)
Methadone Maintenance, %
CD4 count, mean (SD), cells/μL
Log10 Viral Load, mean (SD)
AIDS, %
Antiretroviral treatment, %

Characteristic
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Table 1
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HIVFHVIQ<90
N = 18
35.2(5.2)
61.1
10.6(1.7)a
2.7(4.1)a
3.7(2.9)
13.1(9.6)
37.5
814(195)a
----

HIVFHVIQ≥90
N=9
38.0(8.2)
44.4
13.6(2.5)b
3.3(6.3)a
1.8(2.6)
10.4(5.8)
25
816(323)a
----

HIVFH+
VIQ<90
N = 22
37.8(8.8)
31.8
11.5(1.5)a
4.0(5.5)b
3.5(2.6)
16.1(9.5)
16.7
1055(442)a
----

HIVFH+
VIQ≥90
N = 21
37.7(7.5)
47.6
12.5(1.7)b
4.5(5.8)b
3.7(3.3)
12.1(10.4)
25
903(318)a
----

HIV+
FHVIQ<90
N = 28
40.0(6.0)
50
11.3(1.9)a
3.3(5.3)a
2.5(2.8)
18.7(14.8)
22.2
404(328)b
0.69(0.91)
32.1
75

HIV+
FHVIQ≥90
N = 22
42.2(6.6)
63.6
12.2(1.7)b
3.8(5.6)a
2.7(3.5)
9.5(5.6)
9.1
352(186)b
1.02(0.89)
27.3
68.2

HIV+
FH+
VIQ<90
N = 26
38.2(6.1)
46.2
10.7(1.4)a
7.6(6.4)b
4.3(3.2)
20.3(12.1)
4.0
370(223)b
0.84(1.03)
23.1
50

HIV+
FH+
VIQ≥90
N = 39
40.5(6.3)
59
12.6(2.1)b
5.7(7.0)b
3.5(3.9)
12.2(8.6)
18.4
416(332)b
1.28(0.96)
28.2
66.7

Background Characteristics of the 8 groups. Columns with different subscripts are significantly different (p<0.05).
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